Oncosuppressor proteins of fragile sites are reduced in cervical cancer
- PMID: 19700237
- PMCID: PMC2987609
- DOI: 10.1016/j.canlet.2009.07.017
Oncosuppressor proteins of fragile sites are reduced in cervical cancer
Abstract
FHIT and WWOX are tumor suppressor genes that span the common fragile sites FRA3B and FRA16D, respectively. To analyze possible synergisms among these genes in cervical cancer progression, we considered 159 cervical intraepithelial neoplasias, and 58 invasive squamous cell carcinomas of the uterine cervix. All cases were previously selected as high risk HPV. FHIT and WWOX proteins were examined by immunohistochemistry and their expression was inversely correlated with precancerous vs. invasive lesions. Statistics among biological markers indicated an association between FHIT and WWOX. Protein expression of these two genes was also absent or reduced in cancer cell lines. Thus, WWOX may be considered as a novel important genetic marker in cervical cancer and the association between the altered expression of FHIT and WWOX may be a critical event in the progression of this neoplasia.
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
Figures


Similar articles
-
Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.Mol Cancer Res. 2003 Nov;1(13):940-7. Mol Cancer Res. 2003. PMID: 14638866
-
Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland.Oral Oncol. 2010 Mar;46(3):195-9. doi: 10.1016/j.oraloncology.2009.12.003. Epub 2010 Jan 8. Oral Oncol. 2010. PMID: 20060354
-
Concordant loss of fragile gene expression early in breast cancer development.Pathol Int. 2005 Aug;55(8):471-8. doi: 10.1111/j.1440-1827.2005.01855.x. Pathol Int. 2005. PMID: 15998374
-
Common chromosomal fragile sites and cancer: focus on FRA16D.Cancer Lett. 2006 Jan 28;232(1):37-47. doi: 10.1016/j.canlet.2005.07.041. Epub 2005 Oct 20. Cancer Lett. 2006. PMID: 16242840 Review.
-
Roles of FHIT and WWOX fragile genes in cancer.Cancer Lett. 2006 Jan 28;232(1):27-36. doi: 10.1016/j.canlet.2005.06.048. Epub 2005 Oct 12. Cancer Lett. 2006. PMID: 16225988 Review.
Cited by
-
Common fragile site tumor suppressor genes and corresponding mouse models of cancer.J Biomed Biotechnol. 2011;2011:984505. doi: 10.1155/2011/984505. Epub 2010 Dec 29. J Biomed Biotechnol. 2011. PMID: 21318118 Free PMC article. Review.
-
FHIT and C-MYC expression in cervical histology and cytology as biomarkers for detecting high-grade intraepithelial neoplasia in human papillomavirus-positive women.Cancer Biomark. 2020;27(3):303-312. doi: 10.3233/CBM-182232. Cancer Biomark. 2020. PMID: 31771040 Free PMC article.
-
Downregulated Expression of WWOX in Cervical Carcinoma: A Case-Control Study.Int J Mol Cell Med. 2020 Fall;9(4):273-288. doi: 10.22088/IJMCM.BUMS.9.4.273. Epub 2021 Jan 27. Int J Mol Cell Med. 2020. PMID: 33688485 Free PMC article.
-
Molecular and epigenetic analysis of the fragile histidine triad tumour suppressor gene in equine sarcoids.BMC Vet Res. 2012 Mar 16;8:30. doi: 10.1186/1746-6148-8-30. BMC Vet Res. 2012. PMID: 22424615 Free PMC article.
-
The role of extracellular vesicles in the pathogenesis of gynecological cancer.Front Oncol. 2024 Sep 26;14:1477610. doi: 10.3389/fonc.2024.1477610. eCollection 2024. Front Oncol. 2024. PMID: 39391238 Free PMC article. Review.
References
-
- Brinton LA. Epidemiology of cervical cancer. In: Munoz N, Bosch FX, Shah KV, Meheus A, editors. Epidemiology of Cervical Cancer and Human Papillomavirus. Lyon, France: 1992. pp. 2–23. (IARC Scientific Publication No.109). Overview, in.
-
- The revised Bethesda System for reporting cervical/vaginal cytological diagnoses: report of the 1991 Bethesda workshop. Acta Cytol. 1992;36:273–276. - PubMed
-
- Parker MF, Arroyo GF, Gerardts J, Sabichi AL, Park RC, Taylor RR. Molecular characterization of adenocarcinoma of the cervix. Gynecol. Oncol. 1997;64:242–251. - PubMed
-
- Nguyen HN, Nordquist SR. The Bethesda system and evaluation of abnormal pap smears. Semin. Surg. Oncol. 1999;16:217–221. - PubMed